Genzyme 8-K 2006
QuickLinks -- Click here to rapidly navigate through this document
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d)
DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED):
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
We are a global biotechnology company dedicated to making a major positive impact on the lives of people with serious diseases. Our broad product portfolio is focused on rare genetic disorders, renal disease, orthopaedics, organ transplant, and diagnostic and predictive testing. We are organized into five financial reporting units, which we also consider to be our reporting segments:
Effective January 1, 2006, as a result of changes in how we review our business, certain general and administrative expenses, as well as research and development expenses related to our preclinical development programs, which were formerly allocated amongst our reporting segments and Other, are now allocated to Corporate.
We have revised our segment disclosures as of December 31, 2005, 2004 and 2003 and for the years ended December 31, 2005, 2004 and 2003 to conform to our 2006 presentation. Exhibit 99 to this Current Report on Form 8-K includes:
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.